Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition.

Ben Brumpton, Lars G Fritsche, Jie Zheng, George Davey Smith, Bjørn Olav Åsvold

Research output: Contribution to journalArticle (Academic Journal)peer-review

1 Citation (Scopus)
261 Downloads (Pure)

Search results